Quantitative normalization of spatial metabolomics for molecular signatures of tissue heterogeneity
Ended Project Grant Awarded Last action
- Award ID
- R43GM149044
- Recipient
-
Sygnamap Inc. UEI FH41QG5NZ2Y6
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $712,998
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date
- Originally
- Place of performance
- Texas, USA
Award details come from USAspending.gov.
Description
- Abstract
- The molecular and biochemical basis of tissue heterogeneity in normal and disease states can be addressed with spatial omic analysis. Advances in spatial metabolomic analysis of tissue biopsies using maldi-MSI could enable the identification of numerous biochemical pathways as signatures of specific histopathology features. However, to extract the most robust disease- relevant biomarkers and pathways from spatial omics platforms will require quantitation of spatial molecules for automation and statistical analysis. A key obstacle to adoption of spatial metabolomics is the lack of rigorous normalization of biomolecules across tissue sections. Sygnamap proposes to build MSI-deeppath as a computational platform to quantify spatially distinct metabolite abundancies with histopathologic features. Data from maldi-MSI and bulk metabolomics from serial sections of human kidney and liver tissue will be used as the data source for our platform development. Sygnamap is developing MSI-deeppath, a drug discovery and development computational platform that incorporates ground-breaking improvements in maldi- MSI with computational pathology. Quantitation of spatial metabolomics for automation and statistical analysis as presented in this sbir proposal will enable the extraction of the most robust disease-relevant pathways from metabolites. The rigorous deconvolution of structure-relevant pathways will enable a highly impactful therapeutic target discovery and drug development platform for use by biotech and pharmaceutical companies for development of therapeutics alongside biomarkers.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $356,499 | |
| Original award | $356,499 |
Quick answers
Who received award R43GM149044?
R43GM149044 was awarded to Sygnamap Inc. by National Institute of General Medical Sciences (National Institutes of Health) on January 12, 2023.
How much is award R43GM149044 worth?
$712,998 has been obligated on R43GM149044.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award